GH Research (NASDAQ:GHRS) Stock Price Up 0.1% – Time to Buy?

GH Research PLC (NASDAQ:GHRS)’s share price traded up 0.1% during mid-day trading on Friday . The stock traded as high as $9.73 and last traded at $8.98. 44,624 shares were traded during trading, a decline of 44% from the average session volume of 79,020 shares. The stock had previously closed at $8.97.

Analyst Upgrades and Downgrades

Several research firms recently commented on GHRS. JMP Securities reissued a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th.

GH Research Stock Down 3.0 %

The company has a market cap of $452.66 million, a price-to-earnings ratio of -13.40 and a beta of 0.74. The firm has a 50-day simple moving average of $7.75 and a 200 day simple moving average of $10.38.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. As a group, research analysts expect that GH Research PLC will post -0.85 EPS for the current year.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. lifted its stake in shares of GH Research PLC (NASDAQ:GHRS) by 11.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,251,714 shares of the company’s stock after purchasing an additional 664,381 shares during the quarter. RA Capital Management L.P. owned about 12.02% of GH Research worth $66,643,000 at the end of the most recent quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).